Kini o ṣẹlẹ
Insilico Medicine's Alex Zhavoronkov believes China and AI can deliver the drug industry's next breakthrough. The company is running a Phase 3 trial in China for its AI-discovered drug rentosertib, which is for idiopathic pulmonary fibrosis. Insilico used AI to identify the disease target and develop the molecule to treat it. The company has also launched LongevityBench, a test of large language models' grasp of aging biology.
Alex Zhavoronkov ti oogun Insilico gbagbọ pe China ati AI le ṣe jiṣẹ aṣeyọri atẹle ti ile-iṣẹ oogun naa.
The company is running a Phase 3 trial in China for its AI-discovered drug rentosertib, which is for idiopathic pulmonary fibrosis.
Insilico used AI to identify the disease target and develop the molecule to treat it.
The company has also launched LongevityBench, a test of large language models' grasp of aging biology.
Insilico's strategy of using Chinese resources and talent to develop products for the Chinese market could be a key factor in its success.
Awọn alaye orisun: fortune.com ↗
Kini idi ti o ṣe pataki
Insilico Medicine's success in China and its use of AI to develop drugs could be a game-changer for the pharmaceutical industry. The company's AI-discovered drug rentosertib is in Phase 3 trials, and its LongevityBench test could help improve the understanding of aging biology. Insilico's strategy of using Chinese resources and talent to develop products for the Chinese market could also be a key factor in its success.
Insilico Medicine's success in China and its use of AI to develop drugs could be a game-changer for the pharmaceutical industry.
The company's AI-discovered drug rentosertib is in Phase 3 trials, and its LongevityBench test could help improve the understanding of aging biology.
Insilico's strategy of using Chinese resources and talent to develop products for the Chinese market could also be a key factor in its success.
The company's use of AI could help improve the understanding of aging biology and lead to the development of new treatments.
Insilico's success could lead to a shift in the way drugs are developed and marketed.
Ibaraẹnisọrọ Mechanism: Bii O Ṣe Nṣiṣẹ Lootọ
Ṣawari imọ-ẹrọ abẹlẹ lẹhin idagbasoke yii ni ibaraenisọrọ.
A route planner searches possible journeys using explicit rules. What does this illustrate about AI?
Kini lati wo tókàn
Insilico Medicine's progress in China and its use of AI to develop drugs will be closely watched by the pharmaceutical industry. The company's success could lead to a shift in the way drugs are developed and marketed, and its use of AI could help improve the understanding of aging biology.
Insilico Medicine's progress in China and its use of AI to develop drugs will be closely watched by the pharmaceutical industry.
The company's success could lead to a shift in the way drugs are developed and marketed.
Insilico's use of AI could help improve the understanding of aging biology and lead to the development of new treatments.
The company's strategy of using Chinese resources and talent to develop products for the Chinese market could be a key factor in its success.
Insilico's success could help address the issue of longevity inequality.